Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease

被引:11
作者
Han, Jinsol [1 ]
Lee, Chanbin [1 ,2 ]
Hur, Jin [3 ,4 ]
Jung, Youngmi [1 ,5 ]
机构
[1] Pusan Natl Univ, Coll Nat Sci, Dept Integrated Biol Sci, Pusan 46241, South Korea
[2] Pusan Natl Univ, Inst Syst Biol, Coll Nat Sci, Pusan 46241, South Korea
[3] Pusan Natl Univ, Dept Convergence Med, Sch Med, Yangsan 50612, South Korea
[4] Pusan Natl Univ, PNU GRAND Convergence Med Sci Educ Res Ctr, Sch Med, Yangsan 50612, South Korea
[5] Pusan Natl Univ, Coll Nat Sci, Dept Biol Sci, Pusan 46241, South Korea
基金
新加坡国家研究基金会;
关键词
alcoholic liver disease; therapeutics; mesenchymal stem cells; cell-free therapy; INDUCED OXIDATIVE STRESS; ADENOSYL-L-METHIONINE; TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; N-ACETYLCYSTEINE; VITAMIN-E; BONE-MARROW; S-ADENOSYLMETHIONINE; SIGNAL TRANSDUCER; CONTROLLED-TRIAL;
D O I
10.3390/cells12010022
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Alcoholic liver disease (ALD) is a globally prevalent chronic liver disease caused by chronic or binge consumption of alcohol. The therapeutic efficiency of current therapies for ALD is limited, and there is no FDA-approved therapy for ALD at present. Various strategies targeting pathogenic events in the progression of ALD are being investigated in preclinical and clinical trials. Recently, mesenchymal stem cells (MSCs) have emerged as a promising candidate for ALD treatment and have been tested in several clinical trials. MSC-released factors have captured attention, as they have the same therapeutic function as MSCs. Herein, we focus on current therapeutic options, recently proposed strategies, and their limitations in ALD treatment. Also, we review the therapeutic effects of MSCs and those of MSC-related secretory factors on ALD. Although accumulating evidence suggests the therapeutic potential of MSCs and related factors in ALD, the mechanisms underlying their actions in ALD have not been well studied. Further investigations of the detailed mechanisms underlying the therapeutic role of MSCs in ALD are required to expand MSC therapies to clinical applications. This review provides information on current or possible treatments for ALD and contributes to our understanding of the development of effective and safe treatments for ALD.
引用
收藏
页数:20
相关论文
共 230 条
[1]   Effect of alcohol on clinical complications of hepatitis virus-induced liver cirrhosis: a consecutive ten-year study [J].
Abassa, Kodjo-Kunale ;
Xiao-Ying Wu ;
Xiu-Ping Xiao ;
Hao-Xiong Zhou ;
Yun-Wei Guo ;
Wu, Bin .
BMC GASTROENTEROLOGY, 2022, 22 (01)
[2]   Mitochondrial dysfunction and alcohol-associated liver disease: a novel pathway and therapeutic target [J].
Abdallah, Mohamed A. ;
Singal, Ashwani K. .
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
[3]   Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial [J].
Akriviadis, E ;
Botla, R ;
Briggs, W ;
Han, S ;
Reynolds, T ;
Shakil, O .
GASTROENTEROLOGY, 2000, 119 (06) :1637-1648
[4]   Mesenchymal stromal cell therapy for liver diseases [J].
Alfaifi, Mohammed ;
Eom, Young Woo ;
Newsome, Philip N. ;
Baik, Soon Koo .
JOURNAL OF HEPATOLOGY, 2018, 68 (06) :1272-1285
[5]   Protective effects of antioxidant raxofelast in alcohol-induced liver disease in mice [J].
Altavilla, D ;
Seminara, P ;
Squadrito, G ;
Minutoli, L ;
Passaniti, M ;
Bitto, A ;
Calapai, G ;
Calò, M ;
Caputi, AP ;
Squadrito, F .
PHARMACOLOGY, 2005, 74 (01) :6-14
[6]  
Aly Riham Mohamed, 2020, Stem Cell Investig, V7, P8, DOI 10.21037/sci-2020-001
[7]   Milk Fat Globule-EGF Factor 8, Secreted by Mesenchymal Stem Cells, Protects Against Liver Fibrosis in Mice [J].
An, Su Yeon ;
Jang, Yu Jin ;
Lim, Hee-Joung ;
Han, Jiyou ;
Lee, Jaehun ;
Lee, Gyunggyu ;
Park, Ji Young ;
Park, Seo-Young ;
Kim, Ji Hyang ;
Do, Byung-Rok ;
Han, Choongseong ;
Park, Hee-Kyung ;
Kim, Ok-Hee ;
Song, Myeong Jun ;
Kim, Say-June ;
Kim, Jong-Hoon .
GASTROENTEROLOGY, 2017, 152 (05) :1174-1186
[8]   S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility [J].
Anstee, Quentin M. ;
Day, Christopher P. .
JOURNAL OF HEPATOLOGY, 2012, 57 (05) :1097-1109
[9]   Naltrexone for the management of alcohol dependence [J].
Anton, Raymond F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (07) :715-721
[10]   An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis [J].
Arab, Juan P. ;
Sehrawat, Tejasav S. ;
Simonetto, Douglas A. ;
Verma, Vikas K. ;
Feng, Dechun ;
Tang, Tom ;
Dreyer, Kevin ;
Yan, Xiaoqiang ;
Daley, William L. ;
Sanyal, Arun ;
Chalasani, Naga ;
Radaeva, Svetlana ;
Yang, Liu ;
Vargas, Hugo ;
Ibacache, Mauricio ;
Gao, Bin ;
Gores, Gregory J. ;
Malhi, Harmeet ;
Kamath, Patrick S. ;
Shah, Vijay H. .
HEPATOLOGY, 2020, 72 (02) :441-453